India's IBPL To Launch Oncology Biotech Products

Demonstrating faith in the Gulf states' appetite for novel drugs, India's Intas Biopharmaceuticals (IBPL) is to register itself in the Gulf Co-operation Council (GCC) region. IBPL is initially planning to launch three products to treat certain cancers and their side effects in the GCC. The products due to be launched are Neukine (rHu G-CSF), Erykine (rHu EPO) and Intalfa (rHu interferon alpha

To read the full article, please choose one of the following options: